Aragen Life Sciences
Robert Ruffolo is a distinguished scientist, globally recognized for his executive leadership in the pharmaceutical industry. He served as the President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008. Prior to Wyeth, Dr Ruffolo served as Senior Vice President, R&D, at SmithKline Beecham Pharmaceuticals (now, GlaxoSmithKline) for 17 years. He has played a significant role in the discovery and development of a number of successful products, including Carvedilol, Ropinirole, Dobutamine and Eprosartan.
Dr Ruffolo has won several prestigious awards, including the Discoverer’s Award in 2008 for his pioneering work on the discovery of Carvedilol for the treatment of congestive heart failure. He has published over 500 full-length publications, edited 15 books, and was Editor-in-Chief of four international pharmacology journals. Dr Ruffolo was appointed to Aragen’s (formerly, GVK BIO) Board of Directors in April 2019.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Aragen Life Sciences
4 followers
Aragen is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health. Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement. At Aragen, we recognize your work is vital, urgent and impacts lives. Our purpose, ‘In every molecule is the possibility for better health’ motivates us to drive the success of your programs, so that we can together transform hope into health for millions of people around the world.